Zobrazeno 1 - 10
of 52
pro vyhledávání: '"Eva Månsson-Brahme"'
Publikováno v:
PLoS ONE, Vol 13, Iss 1, p e0191117 (2018)
Taste and smell alterations have been recognized as common symptoms in relation to various cancers. However, previous research suggests that patients do not receive sufficient support in managing taste and smell alterations. Therefore, the objective
Externí odkaz:
https://doaj.org/article/244315130a684c59a9de4163d22ddb89
Autor:
Johan Hansson, Johan Lyth, Caroline Simberg-Danell, John Carstensen, Eva Månsson-Brahme, Margareta Frohm-Nilsson, Hanna Eriksson
Publikováno v:
International Journal of Cancer. 139:543-553
Little is known about cutaneous malignant melanoma (CMM) among immigrants in Europe. We aimed to investigate clinical characteristics and disease-specific survival among first- and second-generation immigrants in Sweden. This nationwide population-ba
Autor:
Britt-Marie Bernhardson, Kerstin Belqaid, Jenny McGreevy, Wendy V. Wismer, Carol Tishelman, Ylva Orrevall, Eva Månsson-Brahme
Publikováno v:
European Journal of Oncology Nursing. 21:232-241
Purpose Taste and smell alterations (TSAs) are common symptoms in patients with cancer that may interfere with nutritional intake and quality of life. In this study, we explore and describe how characteristics of self-reported TSAs change in individu
Publikováno v:
PLoS ONE, Vol 13, Iss 1, p e0191117 (2018)
PLoS ONE
PLoS ONE
Taste and smell alterations have been recognized as common symptoms in relation to various cancers. However, previous research suggests that patients do not receive sufficient support in managing taste and smell alterations. Therefore, the objective
Autor:
Göran Jönsson, Hildur Helgadottir, Veronica Höiom, Johan Hansson, Eva Månsson-Brahme, Håkan Olsson, Rainer Tuominen
Publikováno v:
International Journal of Cancer. 137:2220-2226
Germline CDKN2A mutations are found in 5-20% of melanoma families. Numerous studies have shown that carriers of CDKN2A mutations have increased risks of non-melanoma cancers, but so far there have been no studies investigating cancer risks in CDKN2A
Autor:
Margareta Frohm-Nilsson, Lena Kanter-Lewensohn, Hanna Eriksson, Ismini Vassilaki, J. Järås, Eva Månsson-Brahme, P. Kjellman, Johan Hansson
Publikováno v:
British Journal of Dermatology. 172:175-186
Summary Background The prognostic impact of several histopathological prognostic features in cutaneous malignant melanoma (CMM) remains controversial. Objectives To assess the independent prognostic value of mitotic rate, regression, tumour-infiltrat
Autor:
Britt-Marie Bernhardson, Wendy V. Wismer, Carol Tishelman, Eva Månsson-Brahme, Jenny McGreevy, Ylva Orrevall, Kerstin Belqaid
Publikováno v:
Acta Oncologica (Stockholm, Sweden)
This study of patients under investigation for lung cancer (LC) aims to: 1) examine the prevalence of self-reported taste and smell alterations (TSAs) and their relationships with demographic and clinical characteristics; and 2) explore nutritional i
Autor:
Christian Ingvar, Johan Lyth, Ulrika Stierner, Johan Hansson, Peter Naredi, C Lindholm, Eva Månsson-Brahme, Gunnar Wagenius
Publikováno v:
British Journal of Dermatology. 168:779-786
Background Survival and prognostic factors for thin melanomas have been studied relatively little in population-based settings. This patient group accounts for the majority of melanomas diagnosed i ...
Autor:
Johan Hansson, Eva Månsson-Brahme, Kamilla Krawiec, Barbro Lundh Rozell, Mari-Anne Hedblad, Henrik Hellborg, Hanna Eriksson, Margareta Frohm-Nilsson, Lena Kanter-Lewensohn
Publikováno v:
Acta Dermato Venereologica. 93:411-416
Clinical management of primary cutaneous melanomas is based on histopathological staging of the tumour. The aim of this study was to investigate, in a non-selected population in clinical practice, the agreement rate between general pathologists and p
Autor:
Peter Gillgren, Christian Ingvar, Henrik Hellborg, Krzysztof T. Drzewiecki, Ulrik Ringborg, Eva Månsson-Brahme, Hans Petter Gullestad, Marianne Niin
Publikováno v:
The Lancet. 378:1635-1642
Summary Background Optimum surgical resection margins for patients with clinical stage IIA–C cutaneous melanoma thicker than 2 mm are controversial. The aim of the study was to test whether survival was different for a wide local excision margin of